MedTrace Logo

Clopidogrel Pharmacogenetic Score System

NCT01990989 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2013-11-25

No results posted yet for this study

Summary

The aim of the present study is to evaluate candidate variables,including Cytochrome P450 2C19(CYP2C19) genotypes, clinical and demographic variables,to establish a simple risk score that can be easily adopted by clinicians to identify patients who are at risk for HPR and composite cardiovascular outcomes in Chinese Han patients treated with dual antiplatelet therapy.

Conditions

  • Acute Coronary Syndrome

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • Tong Yin, Dr. · Institute of Geriatric Cardiology, General Hospital of People's Liberation Army, Beijing China

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01990989 on ClinicalTrials.gov